-
公开(公告)号：US20230330259A1
公开(公告)日：2023-10-19
申请号：US18313856
申请日：2023-05-08
发明人： Anna A. Schwendeman , Yuqing Eugene Chen , Yanhong Guo , Jifeng Zhang , Wenmin Yuan , Emily Morin
CPC分类号： A61K47/6917 , A61K9/5169 , A61K49/008 , A61K49/0032 , A61P9/00 , A61K45/06 , A61K47/02
摘要： The present invention relates to nanoparticles complexed with therapeutic agents configured for treating cardiovascular related disorders, and methods of synthesizing the same. In particular, the present invention is directed to compositions comprising synthetic HDL (sHDL) nanoparticles carrying therapeutic agents configured for treating cardiovascular related disorders, methods for synthesizing such sHDL nanoparticles, as well as systems and methods utilizing such sHDL nanoparticles (e.g., in diagnostic and/or therapeutic settings (e.g., for the delivery of therapeutic agents, imaging agents, and/or targeting agents (e.g., in cardiovascular disease diagnosis and/or therapy, etc.))).
-
公开(公告)号：US20180250419A1
公开(公告)日：2018-09-06
申请号：US15561372
申请日：2016-03-25
发明人： Anna A. Schwendeman , Yuqing Eugene Chen , Yanhong Guo , Jifeng Zhang , Wenmin Yuan , Emily Morin
CPC分类号： A61K47/6917 , A61K9/0019 , A61K9/5169 , A61K31/145 , A61K31/192 , A61K31/4439 , A61K38/49 , A61K45/06 , A61K47/02 , A61K49/0032 , A61K49/008 , A61K2300/00 , A61P9/00
摘要： The present invention relates to nanoparticles complexed with therapeutic agents configured for treating cardiovascular related disorders, and methods of synthesizing the same. In particular, the present invention is directed to compositions comprising synthetic HDL (sHDL) nanoparticles carrying therapeutic agents configured for treating cardiovascular related disorders, methods for synthesizing such sHDL nanoparticles, as well as systems and methods utilizing such sHDL nanoparticles (e.g., in diagnostic and/or therapeutic settings (e.g., for the delivery of therapeutic agents, imaging agents, and/or targeting agents (e.g., in cardiovascular disease diagnosis and/or therapy, etc.))).
-
3.发明申请Cholesterol Ester-Depleting Nanomedicine for Non-toxic Cancer Chemotherapy 审中-公开用于无毒性癌症化疗的胆固醇酯消耗纳米医药公开(公告)号：US20160199497A1
公开(公告)日：2016-07-14
申请号：US14850941
申请日：2015-09-10
发明人： Ji-xin Cheng , Seung Young Lee
IPC分类号： A61K47/42 , A61K31/255
CPC分类号： A61K47/42 , A61K9/0019 , A61K9/08 , A61K31/255 , A61K49/0032 , A61K49/008 , A61K2300/00
摘要： The present invention provides a formulation for reducing the hydrophobicity of ACAT-1 inhibitors. Methods for using the formulation of the present invention are also provided.
摘要翻译： 本发明提供了用于降低ACAT-1抑制剂疏水性的制剂。 还提供了使用本发明制剂的方法。
-
4.发明申请Conditional Mst Overexpressing Construct And Conditional Myostatin Overexpressing Transgenic Mouse 有权条件Mst过表达构建和条件肌生成抑制素过表达转基因小鼠公开(公告)号：US20130219527A1
公开(公告)日：2013-08-22
申请号：US13542741
申请日：2012-07-06
IPC分类号： G01N33/50
CPC分类号： A61K49/008 , A01K67/0275 , A01K2217/15 , A01K2217/203 , A01K2267/03 , A61K49/0008 , C12N15/8509 , G01N33/5023 , G01N33/5088 , G01N33/6887 , G01N2800/10
摘要： Provided herein are novel nucleic acid sequences, vectors comprising such nucleic acid sequences, host cells comprising such vectors, and transgenic animals comprising such nucleic acid sequences, and related molecules and methods relating thereto. Such novel nucleic acid sequences, vectors comprising such nucleic acid sequences, host cells comprising such vectors, and transgenic animals comprising such nucleic acid sequences, and related molecules and methods provide conditional overexpression of genes, such as myostatin, and transgenic animals conditionally overexpression genes, such as myostatin.
摘要翻译： 本文提供了新的核酸序列，包含此类核酸序列的载体，包含此类载体的宿主细胞和包含该核酸序列的转基因动物以及与之相关的相关分子和方法。 包含此类核酸序列的载体，包含此类载体的宿主细胞和包含该核酸序列的转基因动物以及相关分子和方法提供了条件性过表达基因，例如肌生成抑制素和转基因动物条件性过表达基因， 如肌肉生长抑制素。
-
公开(公告)号：US20100267846A1
公开(公告)日：2010-10-21
申请号：US12679519
申请日：2008-09-24
CPC分类号： A61K31/683 , A61K9/127 , A61K9/1277 , A61K31/685 , A61K38/177 , A61K47/6919 , A61K47/6925 , A61K49/0043 , A61K49/008
摘要： An isolated caveolin containing vesicle comprising a caveolin protein and at least one lipid, wherein at least about 30% of the at least one lipid is selected from phosphatidylethanolamine and phosphatidylglycerol is disclosed. Also disclosed is a method of making an isolated caveolin containing vesicle, an isolated caveolin containing vesicle comprising a recombinant caveolin protein, an isolated caveolin containing delivery vesicle, a method of making an isolated caveolin containing delivery vesicle and a method of treatment of a disease or condition by delivery of a molecule using the isolated caveolin containing delivery vesicle.
摘要翻译： 包含含有窖蛋白和至少一种脂质的分离的含有小窝蛋白的囊泡，其中至少一种脂质的至少约30％选自磷脂酰乙醇胺和磷脂酰甘油。 还公开了制备含有囊泡的分离的小窝蛋白的方法，含有重组窖蛋白的分离的含窖蛋白的囊泡，含有分离的含窖蛋白的递送囊泡，分离的含有小窝蛋白的分泌小泡的方法，以及治疗疾病的方法或 通过使用分离的含窖蛋白的递送囊泡递送分子的条件。
-
公开(公告)号：US20080253960A1
公开(公告)日：2008-10-16
申请号：US11547015
申请日：2005-04-01
申请人： Gang Zheng , Jerry D. Glickson
发明人： Gang Zheng , Jerry D. Glickson
IPC分类号： A61K51/00 , A61K47/42 , A61K49/06 , A61K49/22 , A61K31/337 , A61K31/704 , A61K31/164 , A61K31/433 , A61K31/137 , A61K31/138 , A61K31/675 , A61K49/00 , A61K49/04 , A61K38/02
CPC分类号： A61K49/0052 , A61K41/0071 , A61K47/6917 , A61K47/6929 , A61K49/008 , A61K49/14 , A61K49/1806 , B82Y5/00
摘要： The present invention provides a non-naturally occurring lipoprotein nanoplatform (“LBNP”) comprising at least one cell surface receptor ligand; at least one lipoprotein; and at least one diagnostic agent and/or at least one therapeutic agent. In embodiments of the present invention, the cell surface receptor ligand is not a low-density lipoprotein receptor ligand and the cell surface receptor ligand is covalently bonded to the apoprotein. The present invention also provides pharmaceutical formulations comprising LBNPs and methods of making the LBNPs.
摘要翻译： 本发明提供了包含至少一种细胞表面受体配体的非天然存在的脂蛋白纳米平板（“LBNP”）; 至少一种脂蛋白; 和至少一种诊断剂和/或至少一种治疗剂。 在本发明的实施方案中，细胞表面受体配体不是低密度脂蛋白受体配体，并且细胞表面受体配体与载脂蛋白共价结合。 本发明还提供了包含LBNP的药物制剂和制备LBNP的方法。
-
公开(公告)号：US20230346703A1
公开(公告)日：2023-11-02
申请号：US17925262
申请日：2021-05-12
CPC分类号： A61K9/1275 , A61K9/1277 , A61K49/008
摘要： The invention concerns nanovesicles of nanostructured myelin and uses thereof in the treatment of demyelinating and neurodegenerative diseases of the central (CNS) and peripheral (PNS) nervous system. Under another aspect, processes for the preparation of myelin nanovesicles having particular characteristics that make them suitable for recovery of the myelin sheath, where it is compromised, as a drug delivery system for CNS or PNS, and for immunotolerance, are described.
-
公开(公告)号：US20160030599A1
公开(公告)日：2016-02-04
申请号：US14776342
申请日：2014-03-13
发明人： Eva Jakab Toth , Stéphane Petoud , Sara Lacerda , Célia Bonnet
IPC分类号： A61K49/00 , A61K31/136 , A61K31/4745 , A61K31/704
CPC分类号： A61K49/0084 , A61K31/136 , A61K31/137 , A61K31/4745 , A61K31/704 , A61K47/6911 , A61K47/6917 , A61K49/008
摘要： The present invention relates to particles, useful for drug release detection, comprising: at least one luminescent metal complex of formula [Ln].[L], wherein: Ln is a lanthanide ion, L is an organic ligand comprising a hydrophilic unit with at least 6 chelating groups chosen from the group consisting of hydroxyl, carboxyl, optionally in the carboxylate form, carbonyl, ether, phosphonate, phosphinate, thiolate, amino and imino functions, and at least one drug comprising a conjugated aromatic system, wherein said drug is not covalently bonded to the metal complex, said particle having a size comprised from 3 nm to 2000 nm, and wherein the distribution of the metal complex and the drug within the particle is such that the mean distance between a drug molecule and a metal complex is less than 15 nm.
摘要翻译： 本发明涉及用于药物释放检测的颗粒，其包含：至少一种式[Ln]的发光金属络合物[L]，其中：Ln是镧系元素离子，L是包含亲水单元的有机配体， 选自羟基，羧基，任选以羧酸盐形式，羰基，醚，膦酸盐，次膦酸盐，硫醇盐，氨基和亚氨基官能团的至少6个螯合基团，和至少一种包含共轭芳族体系的药物，其中所述药物是 所述颗粒具有3nm至2000nm的尺寸，并且其中金属络合物和药物在颗粒内的分布使得药物分子和金属络合物之间的平均距离为 小于15nm。
-
公开(公告)号：US08282930B2
公开(公告)日：2012-10-09
申请号：US12679519
申请日：2008-09-24
CPC分类号： A61K31/683 , A61K9/127 , A61K9/1277 , A61K31/685 , A61K38/177 , A61K47/6919 , A61K47/6925 , A61K49/0043 , A61K49/008
摘要： An isolated caveolin containing vesicle comprising a caveolin protein and at least one lipid, wherein at least about 30% of the at least one lipid is selected from phosphatidylethanolamine and phosphatidylglycerol is disclosed. Also disclosed is a method of making an isolated caveolin containing vesicle, an isolated caveolin containing vesicle comprising a recombinant caveolin protein, an isolated caveolin containing delivery vesicle, a method of making an isolated caveolin containing delivery vesicle and a method of treatment of a disease or condition by delivery of a molecule using the isolated caveolin containing delivery vesicle.
摘要翻译： 包含含有窖蛋白和至少一种脂质的分离的含有小窝蛋白的囊泡，其中至少一种脂质的至少约30％选自磷脂酰乙醇胺和磷脂酰甘油。 还公开了制备含有囊泡的分离的小窝蛋白的方法，含有重组窖蛋白的分离的含窖蛋白的囊泡，含有分离的含窖蛋白的递送囊泡，分离的含有小窝蛋白的分泌小泡的方法，以及治疗疾病的方法或 通过使用分离的含窖蛋白的递送囊泡递送分子的条件。
-
10.发明授权Conditional Mst overexpressing construct and conditional myostatin overexpressing transgenic mouse 有权有条件的Mst过表达构建体和条件肌生成抑制素过表达转基因小鼠公开(公告)号：US08222478B2
公开(公告)日：2012-07-17
申请号：US12398994
申请日：2009-03-05
IPC分类号： A01K67/00 , A01K67/033 , A01K67/027
CPC分类号： A61K49/008 , A01K67/0275 , A01K2217/15 , A01K2217/203 , A01K2267/03 , A61K49/0008 , C12N15/8509 , G01N33/5023 , G01N33/5088 , G01N33/6887 , G01N2800/10
摘要： Provided herein are novel nucleic acid sequences, vectors comprising such nucleic acid sequences, host cells comprising such vectors, and transgenic animals comprising such nucleic acid sequences, and related molecules and methods relating thereto. Such novel nucleic acid sequences, vectors comprising such nucleic acid sequences, host cells comprising such vectors, and transgenic animals comprising such nucleic acid sequences, and related molecules and methods provide conditional overexpression of genes, such as myostatin, and transgenic animals conditionally overexpression genes, such as myostatin.
摘要翻译： 本文提供了新的核酸序列，包含此类核酸序列的载体，包含此类载体的宿主细胞和包含该核酸序列的转基因动物以及与之相关的相关分子和方法。 包含此类核酸序列的载体，包含此类载体的宿主细胞和包含该核酸序列的转基因动物以及相关分子和方法提供了条件性过表达基因，例如肌生成抑制素和转基因动物条件性过表达基因， 如肌肉生长抑制素。
-
-
-
-
-
-
-
-
-
搜索结果
14 条记录 (耗时 0.015 秒)
